InvestorsObserver
×
News Home

Do Analysts Expect Cumberland Pharmaceuticals, Inc. (CPIX) Stock to Rise?

Friday, January 22, 2021 02:27 PM | InvestorsObserver Analysts

Mentioned in this article

Do Analysts Expect Cumberland Pharmaceuticals, Inc. (CPIX) Stock to Rise?

InvestorsObserver is giving Cumberland Pharmaceuticals, Inc. (CPIX) an Analyst Rating Rank of 79, meaning CPIX is ranked higher by analysts than 79% of stocks. The average projection by analysts for CPIX is $8.5 over the next 12 months and analyst’s classify the stock as a Strong Buy

Overall Score - 5
Wall Street analysts are rating CPIX a Strong Buy today. Find out what this means to you and get the rest of the rankings on CPIX!

Why are Analyst Ratings Important?

Analysts know the inner workings of the companies they follow better than anyone but the companies’ management. You can learn a lot about a company from studying the financial statements, but analysts ask questions on conference calls and understand the intricacies of each of the businesses they cover. Analysts understand how bad weather in one part of the world can disrupt supply chains, or disrupt shopping patterns. This lets traders make decisions before a quarterly report that could be worse than expected.

InvestorsObserver aggregates the ratings of all the analysts covering a given stock, takes the average of those ratings and then percentile ranks the averages. That provides a level of granularity that is significantly better than just the three levels provided by traditional buy/hold/sell ratings.

What's Happening With Cumberland Pharmaceuticals, Inc. Stock Today?

Cumberland Pharmaceuticals, Inc. (CPIX) stock is trading at $3.21 as of 2:23 PM on Friday, Jan 22, a loss of -$0.01, or -0.31% from the previous closing price of $3.22. Volume today is high. So far 328,580 shares have traded compared to average volume of 29,429 shares. The stock has traded between $3.12 and $3.58 so far today.

Click Here to get the full report on Cumberland Pharmaceuticals, Inc. (CPIX) Stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App